Introduction

This page provides a comprehensive analysis of the known insider trading history of Jeffrey Bacha. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Jeffrey Bacha has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
Director 64,049
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Jeffrey Bacha. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Jeffrey Bacha as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2018-04-03 2018-03-30 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 64,049 0.28 3.20 563 204,957
2018-01-03 2017-12-31 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 63,873 0.28 3.20 563 204,394
2018-01-03 2017-12-22 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		A - Award 93,600 93,600
2018-01-03 2017-12-22 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		D - Sale to Issuer -93,600 0 -100.00
2018-01-03 2017-12-22 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		A - Award 87,500 87,500
2018-01-03 2017-12-22 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		D - Sale to Issuer -87,500 0 -100.00
2018-01-03 2017-12-22 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		A - Award 37,500 37,500
2018-01-03 2017-12-22 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		D - Sale to Issuer -37,500 0 -100.00
2017-10-10 2017-10-06 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 2,450 63,697 4.00 0.88 2,156 56,053
2017-10-10 2017-10-06 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 7,550 61,247 14.06 0.87 6,568 53,285
2017-10-02 2017-09-29 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 53,697 0.33 3.20 563 171,830
2017-07-05 2017-06-30 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 53,521 0.33 3.20 563 171,267
2017-06-28 2017-06-26 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 6,700 53,345 14.36 3.60 24,120 192,042
2017-06-06 2017-06-06 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 5,000 46,645 12.01 2.12 10,600 98,887
2017-05-08 2017-05-05 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 2,500 41,645 6.39 2.20 5,500 91,619
2017-04-04 2017-03-31 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 39,145 0.45 3.20 563 125,264
2017-02-22 2017-02-17 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		A - Award 93,600 93,600
2017-02-02 2017-02-01 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 4,000 38,969 11.44 5.00 20,000 194,845
2017-01-03 2016-12-31 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 34,969 0.51 3.20 563 111,901
2016-10-05 2016-10-03 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 176 34,793 0.51 3.20 563 111,338
2016-07-19 2016-07-18 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		J - Other 120 34,617 0.35 3.20 384 110,774
2016-05-03 2016-04-29 4 DMPI DelMar Pharmaceuticals, Inc.
Series B Preferred Stock 		P - Purchase 3,125 3,125 8.00 25,000 25,000
2015-11-30 2015-11-25 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 7,500 137,985 5.75 1.47 11,025 202,838
2015-10-09 2015-10-08 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 200 130,485 0.15 0.78 156 101,778
2015-10-09 2015-10-08 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 2,800 130,285 2.20 0.80 2,240 104,215
2015-09-22 2015-09-18 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 4,000 127,485 3.24 0.83 3,320 105,813
2015-07-28 2015-07-25 4 DMPI DelMar Pharmaceuticals, Inc.
Warrant 		P - Purchase 10,000 60,000 20.00 0.00 10 60
2015-07-28 2015-07-25 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 10,000 123,485 8.81 0.60 6,000 74,091
2015-07-16 2015-07-16 4 DMPI DelMar Pharmaceuticals, Inc.
Warrant 		P - Purchase 50,000 50,000 0.00 50 50
2015-07-16 2015-07-16 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 50,000 113,485 78.76 0.60 30,000 68,091
2015-01-22 2015-01-22 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 2,500 63,485 4.10 0.65 1,625 41,265
2015-01-22 2015-01-22 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 5,000 60,985 8.93 0.66 3,300 40,250
2014-12-10 2014-12-09 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 2,500 55,985 4.67 0.90 2,250 50,386
2014-11-26 2014-11-26 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 2,500 53,485 4.90 0.92 2,300 49,206
2014-09-19 2014-09-18 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 4,000 50,985 8.51 0.98 3,920 49,965
2014-09-16 2014-09-15 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 4,985 46,985 11.87 0.75 3,739 35,239
2014-03-20 2014-03-18 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		P - Purchase 10,000 42,000 31.25 1.30 13,000 54,600
2014-02-21 2014-02-21 4 DMPI DelMar Pharmaceuticals, Inc.
COMMON STOCK 		P - Purchase 5,000 32,000 18.52 1.00 5,000 32,000
2014-02-13 2014-02-13 4 DMPI DelMar Pharmaceuticals, Inc.
COMMON STOCK 		P - Purchase 5,000 27,000 22.73 0.80 4,000 21,600
2013-08-22 2013-08-16 4 DMPI DelMar Pharmaceuticals, Inc.
Options (Right to Buy) 		A - Award -350,000 350,000 -50.00
2013-08-07 2013-08-05 4 DMPI DelMar Pharmaceuticals, Inc.
Warrants (Right to Buy) 		C - Conversion -22,000 198,000 -10.00
2013-08-07 2013-08-05 4 DMPI DelMar Pharmaceuticals, Inc.
Common Stock 		C - Conversion 22,000 22,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)